myosin light chain kinase family member 4Genealiases: MLCK4 · SgK085
Q-omics provides the consensus-scored MYLK4 profile across patient tissues and cancer cell-line models. MYLK4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYLK4 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, MYLK4 RNA expression shows 20,205 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where MYLK4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYLK4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYLK4 survival associations across molecular data types. MYLK4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYLK4 RNA expression–survival associations across cancer types. High MYLK4 expression shows unfavorable associations in KICH, but favorable associations in KIRC, HNSC, THYM, READ and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYLK4 RNA expression.
This table summarizes MYLK4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MYLK4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYLK4 shows lower tumor expression in THCA, KICH, HNSC, LUSC and BRCA and higher tumor expression in LIHC. The THCA box plot shows higher MYLK4 RNA expression in normal versus tumor tissue (log2 FC = −0.967, t-test p < 0.001).
This table shows molecular features associated with MYLK4 in patient tissues and cancer cell lines. In patient samples, MYLK4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYLK4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
